Identification of a serum biomarker signature associated with metastatic prostate cancer

Venera Kuci Emruli, Leena Liljedahl, Ulrika Axelsson, Corinna Richter, Lisa Theorin, Anders Bjartell, Hans Lilja, Jenny Donovan , David Neal, Freddie C. Hamdy, Carl A. K. Borrebaeck

Research output: Contribution to journalArticle (Academic Journal)peer-review

5 Downloads (Pure)


Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.

Experimental design
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.

A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.

Conclusions and clinical relevance
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
Original languageEnglish
Number of pages13
JournalProteomics - Clinical applications
Early online date13 Feb 2021
Publication statusPublished - 4 May 2021


  • affinity proteomics
  • antibody microarrays
  • biomarkers
  • cancer
  • prostate cancer

Fingerprint Dive into the research topics of 'Identification of a serum biomarker signature associated with metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this